After intravenous administration of ConA, rats for oral pharmacokinetic study were fasted for 12 h before oral administration of CdG. ConA-induced VLI model rats were intravenously (n = 4) or orally (n = 4) administered a single injection of CdG (1 mg/kg), which was synthesized as reported previously.5 (link)) Blood samples (250 μL) were collected from the femoral vein using a heparinized syringe at 3, 15, 30, 45, 60, 90 and 180 min after intravenous administration and at 5, 15, 30, 45, 60, 90 and 180 min after oral administration. The blood samples were centrifuged at 3,000 rpm for 10 min to obtain plasma. After the last sampling of blood, all rats were euthanized, and the kidneys and liver were then removed from the rats that have been orally administered CdG. The concentration of CdG in plasma and organs were quantitated using LC-MS as reported previously.6 (link)) The LC-MS system was consisted of a Waters ACQUITY ultra performance liquid chromatography (UPLC) system with a time-of-flight (TOF)-MS system (Xevo® G2-S Tof, Waters, flow rate: 0.4 mL/min) and a ACQUITY UPLC BEH Phenyl column (2.1× 100 mm, 1.7 μm particle size, Waters, 40°C). The lower limit of quantification of CdG was 15 ng/mL in this established method.6 (link))